312 related articles for article (PubMed ID: 31084383)
1. Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US.
Amin A; Deitelzweig S; Bucior I; Lin J; Lingohr-Smith M; Menges B; Neuman WR
J Med Econ; 2019 Nov; 22(11):1119-1125. PubMed ID: 31084383
[No Abstract] [Full Text] [Related]
2. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations.
Spyropoulos AC; Lin J
J Manag Care Pharm; 2007; 13(6):475-86. PubMed ID: 17672809
[TBL] [Abstract][Full Text] [Related]
3. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
Lin J; Lingohr-Smith M; Kwong WJ
J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
[TBL] [Abstract][Full Text] [Related]
5. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.
Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Schein J; Kaatz S
J Manag Care Pharm; 2012 Jun; 18(5):363-74. PubMed ID: 22663169
[TBL] [Abstract][Full Text] [Related]
6. Resource utilization and charges of patients with and without diagnosed venous thromboembolism during primary hospitalization and after elective inpatient surgery: a retrospective study.
Sepassi A; Chingcuanco F; Gordon R; Meier A; Divino V; DeKoven M; Ben-Joseph R
J Med Econ; 2018 Jun; 21(6):595-602. PubMed ID: 29480088
[TBL] [Abstract][Full Text] [Related]
7. Comparison of inpatient admission rates of patients treated with apixaban vs. warfarin for venous thromboembolism in the emergency department.
Deitelzweig S; Hlavacek P; Mardekian J; Rosenblatt L; Russ C; Tuell K; Lingohr-Smith M; Lin J; Guo JD
Hosp Pract (1995); 2020 Feb; 48(1):41-48. PubMed ID: 31976776
[No Abstract] [Full Text] [Related]
8. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States.
LaMori JC; Shoheiber O; Mody SH; Bookhart BK
Clin Ther; 2015 Jan; 37(1):62-70. PubMed ID: 25524389
[TBL] [Abstract][Full Text] [Related]
9. Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States.
Deitelzweig S; Guo JD; Hlavacek P; Lin J; Wygant G; Rosenblatt L; Gupta A; Pan X; Mardekian J; Lingohr-Smith M; Menges B; Marshall A; Nadkarni A
Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):261S-268S. PubMed ID: 30433823
[TBL] [Abstract][Full Text] [Related]
10. Economic burden of recurrent venous thromboembolism: analysis from a U.S. hospital perspective.
Casciano JP; Dotiwala Z; Kemp R; Li C; Cai J; Preblick R
Am J Health Syst Pharm; 2015 Feb; 72(4):291-300. PubMed ID: 25631836
[TBL] [Abstract][Full Text] [Related]
11. Impact of postoperative venous thromboembolism on Medicare recipients undergoing total hip replacement or total knee replacement surgery.
Baser O; Supina D; Sengupta N; Wang L; Kwong L
Am J Health Syst Pharm; 2010 Sep; 67(17):1438-45. PubMed ID: 20720243
[TBL] [Abstract][Full Text] [Related]
12. The Incidence and Economic Burden of In-Hospital Venous Thromboembolism in the United States.
Shahi A; Chen AF; Tan TL; Maltenfort MG; Kucukdurmaz F; Parvizi J
J Arthroplasty; 2017 Apr; 32(4):1063-1066. PubMed ID: 27866951
[TBL] [Abstract][Full Text] [Related]
13. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study.
Burke JP; Hunsche E; Régulier E; Nagao M; Buzinec P; Drake Iii W
Am J Manag Care; 2015 Jan; 21(3 Suppl):s47-58. PubMed ID: 25734573
[TBL] [Abstract][Full Text] [Related]
14. Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status.
Weeda ER; Peacock WF; Fermann GJ; Baugh CW; Wells PS; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
Int J Clin Pract; 2017 Jan; 71(1):. PubMed ID: 28097761
[TBL] [Abstract][Full Text] [Related]
15. High Burden of 30-Day Readmissions After Acute Venous Thromboembolism in the United States.
Secemsky EA; Rosenfield K; Kennedy KF; Jaff M; Yeh RW
J Am Heart Assoc; 2018 Jun; 7(13):. PubMed ID: 29945913
[TBL] [Abstract][Full Text] [Related]
16. Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy.
Dasta JF; Pilon D; Mody SH; Lopatto J; Laliberté F; Germain G; Bookhart BK; Lefebvre P; Nutescu EA
Thromb Res; 2015 Feb; 135(2):303-10. PubMed ID: 25555319
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of hospitalization costs for 278 venous thromboeboembolism patients with health insurance in China].
Wu JJ; Yang L
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 45(3):437-42. PubMed ID: 23774924
[TBL] [Abstract][Full Text] [Related]
18. Venous Thromboembolism Prophylaxis and Risk in the Inpatient and Outpatient Continuum of Care Among Hospitalized Acutely Ill Patients in the US: A Retrospective Analysis.
Amin A; Neuman WR; Lingohr-Smith M; Menges B; Lin J
Adv Ther; 2019 Jan; 36(1):59-71. PubMed ID: 30543037
[TBL] [Abstract][Full Text] [Related]
19. Which Clinical and Patient Factors Influence the National Economic Burden of Hospital Readmissions After Total Joint Arthroplasty?
Kurtz SM; Lau EC; Ong KL; Adler EM; Kolisek FR; Manley MT
Clin Orthop Relat Res; 2017 Dec; 475(12):2926-2937. PubMed ID: 28108823
[TBL] [Abstract][Full Text] [Related]
20. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients.
Ollendorf DA; Vera-Llonch M; Oster G
Am J Health Syst Pharm; 2002 Sep; 59(18):1750-4. PubMed ID: 12298113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
